{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062914","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.440409+00:00","generated_at":"2026-06-08T05:20:13.050136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arcellx Q3 net loss $39.3M vs $92.9M prior year; cash $482.7M; CART-ddBCMA data at ASH with 22mo follow-up","bullets":["Net loss narrowed to $39.3M from $92.9M in Q3 2022; collaboration revenue $15.0M from Kite license.","Cash, equivalents and marketable securities $482.7M; company expects to fund operations into 2026.","CART-ddBCMA Phase 1 data: median DOR, PFS and OS not reached at 22-month median follow-up; no delayed neurotoxicity.","Upcoming ASH oral presentation on Dec 11, 2023 with new data at median 26.5-month follow-up.","R&D expenses $43.8M (down from $83.5M) primarily due to non-cash charge for Lonza manufacturing agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062914","json":"https://secwatch.observer/filing/0000950170-23-062914.json","markdown":"https://secwatch.observer/filing/0000950170-23-062914.md","text":"https://secwatch.observer/filing/0000950170-23-062914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023062914/0000950170-23-062914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023062914/aclx-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:20:13.050136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8449697535e5ec94afacdcae0f82dc3abb4d14c4","claim":"Arcellx, Inc. reported third quarter ended September 30, 2023 results: revenue $15.0 million, net income Net loss was $39.3 million.","evidence_excerpt":"million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026. Collaboration revenue: Collaboration revenue was $15.0 million and zero for the quarters ended September 30, 2023 and 2022, respectively. The revenue results for the three months ended September 30, 2023 is from the recognition of research","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023062914/0000950170-23-062914-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$15.0 million"},{"label":"Net income","value":"Net loss was $39.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}